1. Home
  2. CSWC vs MDWD Comparison

CSWC vs MDWD Comparison

Compare CSWC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital Southwest Corporation

CSWC

Capital Southwest Corporation

HOLD

Current Price

$22.19

Market Cap

1.2B

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.97

Market Cap

230.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSWC
MDWD
Founded
1961
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Textiles
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
230.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
CSWC
MDWD
Price
$22.19
$18.97
Analyst Decision
Buy
Strong Buy
Analyst Count
5
2
Target Price
$23.50
$37.50
AVG Volume (30 Days)
578.5K
95.0K
Earning Date
11-03-2025
11-20-2025
Dividend Yield
11.46%
N/A
EPS Growth
N/A
N/A
EPS
1.62
N/A
Revenue
$217,271,000.00
$20,932,000.00
Revenue This Year
$13.78
$15.89
Revenue Next Year
$7.08
$25.33
P/E Ratio
$13.73
N/A
Revenue Growth
11.39
6.15
52 Week Low
$17.46
$14.14
52 Week High
$23.86
$22.51

Technical Indicators

Market Signals
Indicator
CSWC
MDWD
Relative Strength Index (RSI) 67.09 59.99
Support Level $21.22 $18.71
Resistance Level $22.52 $19.63
Average True Range (ATR) 0.31 0.71
MACD 0.10 0.18
Stochastic Oscillator 83.10 79.22

Price Performance

Historical Comparison
CSWC
MDWD

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: